124663-30-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Formyl-phoxymethyl)-benzoic acid methyl ester is used as an active pharmaceutical ingredient for its potential antitumor and antiparasitic properties. Its unique chemical structure allows it to target and inhibit specific biological pathways, making it a valuable compound in the development of new drugs and therapies for various diseases.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-(4-Formyl-phoxymethyl)-benzoic acid methyl ester serves as a key compound for further research and development. Its chemical properties and potential biological activities provide a foundation for designing and synthesizing novel drug candidates with improved efficacy and selectivity.
Used in Chemical Industry:
4-(4-Formyl-phoxymethyl)-benzoic acid methyl ester also finds applications in the chemical industry, where it can be utilized as an intermediate in the synthesis of various organic compounds. Its versatile chemical structure allows for further functionalization and modification, enabling the development of new chemical entities with diverse applications.

InChI:InChI=1/C16H14O4/c1-19-16(18)14-6-2-13(3-7-14)11-20-15-8-4-12(10-17)5-9-15/h2-10H,11H2,1H3

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 387343-74-0 methyl 4-((4-((5-chloro-2-oxoindolin-3-yliden)methyl)phenoxy)methyl)-benzoate 

Relevant academic research and scientific papers

SP1-independent inhibition of FOXM1 by modified thiazolidinediones

This research article describes an approach to modify the thiazolidinedione scaffold to produce test drugs capable of binding to, and inhibit, the in vitro transcriptional activity of the oncogenic protein FOXM1. This approach allowed us to obtain FOXM1 i

Synthesis and structure–activity relationship study of novel quinazolinone-based inhibitors of MurA

MurA is an intracellular bacterial enzyme that is essential for peptidoglycan biosynthesis, and is therefore an important target for antibacterial drug discovery. We report the synthesis, in silico studies and extensive structure–activity relationships of a series of quinazolinone-based inhibitors of MurA from Escherichia coli. 3-Benzyloxyphenylquinazolinones showed promising inhibitory potencies against MurA, in the low micromolar range, with an IC50 of 8?μM for the most potent derivative (58). Furthermore, furan-substituted quinazolinones (38, 46) showed promising antibacterial activities, with MICs from 1?μg/mL to 8?μg/mL, concomitant with their MurA inhibitory potencies. These data represent an important step towards the development of novel antimicrobial agents to combat increasing bacterial resistance.

Gram-scale synthesis of a novel core building block for the new GPR40 agonist design

Background: 3-[4-(Benzyloxy)phenyl]propanoic acid moiety is central to many advanced agonists of free fatty acid receptor 1 (FFA1 or GPR40) which are a new, promising class of antidiabetic drugs. An aldehydo carboxylic acid tert-butyl ester building block is required for speedy SAR exploration of analogs of Eli Lilly's GPR40 agonist LY2881835 which was in phase I clinical trials. Methods: The aldehyde functionality of the target building block was masked as methyl carboxylate. The phenylpropionic acid tert-butyl ester portion was constructed using Horner-Wadsworth-Emmons chemistry followed by olefin hydrogenation. The aldehyde function was unmasked via methyl ester hydrolysis, mixed anhydride reduction to alcohol and back-oxidation with manganese (IV) dioxide. Results: The synthesis of the target building block was realized in 7 chemical steps (the final three of which were conducted in succession not requiring interim purifications) involving isolation and characterization of four hitherto undescribed intermediates. Conclusion: The method described is suitable for production of the target alehydo carboxylic acid tertbutyl ester building block on a multigram scale, which will facilitate the parallel synthesis of LY2881835 analogs and expedite the respective SAR exploration.

CARBAMATE DERIVATIVES

Compounds of formula (I) defined herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract.

NOVEL COMPOUNDS

Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstru

PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS

The invention relates to novel compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3

The inhibition of FLT-3 activity is an interesting target for the treatment of acute myeloid leukemia (AML). The serendipitous identification of FLT-3 inhibitors from a CK1/γ-secretase programme provided compounds with dual inhibitory activity. We analyzed the structure-activity relationship of these inhibitors and derivatized them to arrive at compounds with reduced impact on γ-secretase activity and enhanced FLT-3 inhibition.